TRELEGY ELLIPTA Drug Patent Profile

When do Trelegy Ellipta patents expire, and what generic alternatives are available?

Trelegy Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are ten patents protecting this drug.

This drug has two hundred and fifty-two patent family members in fifty-one countries.

The generic ingredient in TRELEGY ELLIPTA is fluticasone furoate; umeclidinium bromide; vilanterol trifenatate. There are twenty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fluticasone furoate; umeclidinium bromide; vilanterol trifenatate profile page.

DrugPatentWatch^® Generic Entry Outlook for Trelegy Ellipta

Trelegy Ellipta was eligible for patent challenges on May 10, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 29, 2030. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRELEGY ELLIPTA

International Patents:	252
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Drug Prices:	Drug price information for TRELEGY ELLIPTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRELEGY ELLIPTA
What excipients (inactive ingredients) are in TRELEGY ELLIPTA?	TRELEGY ELLIPTA excipients list
DailyMed Link:	TRELEGY ELLIPTA at DailyMed

See drug prices for TRELEGY ELLIPTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRELEGY ELLIPTA

Constraining patent/regulatory exclusivity:

9,750,726

NDA:

209482

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRELEGY ELLIPTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Alabama at Birmingham	PHASE2
Baylor Research Institute	Phase 4
GlaxoSmithKline	Phase 4

See all TRELEGY ELLIPTA clinical trials

Pharmacology for TRELEGY ELLIPTA

Drug Class	Anticholinergic Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Cholinergic Antagonists Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for TRELEGY ELLIPTA

TRELEGY ELLIPTA is protected by eleven US patents.

This potential generic entry date is based on patent 9,750,726.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	8,309,572
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes	8,534,281*PED				Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes	12,396,986		Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes	8,309,572

Expired US Patents for TRELEGY ELLIPTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017	RE44874
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020	7,629,335
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017	6,537,983
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017	7,776,895

International Patents for TRELEGY ELLIPTA

When does loss-of-exclusivity occur for TRELEGY ELLIPTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Eurasian Patent Organization

European Patent Office

France

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Norway

Peru

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Turkey

Ukraine

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRELEGY ELLIPTA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	7649701	17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
Cyprus	1116145
South Korea	20080031458	MEDICAMENT DISPENSER
Slovakia	1422003	6alpha,9alpha-difluoro-17alpha-[(2-furanylcarboxyl)oxy]-11beta- hydroxy-16alpha-methyl-3-oxo-androst-1,4,-diene-17beta- carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent

Supplementary Protection Certificates for TRELEGY ELLIPTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1740177	570	Finland
2506844	1890025-8	Sweden		PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117
1425001	14C0028	France		PRODUCT NAME: VILANTEROL OU UN SEL OU UN SOLVATE DE CELUI-CI,EN PARTICULIER LE TRIFENATATE DE VILANTEROL.; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113
1425001	2014/024	Ireland		PRODUCT NAME: VILANTEROL OR A SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131113

Market Dynamics and Financial Trajectory for TRELEGY ELLIPTA

Last updated: December 31, 2025

Executive Summary

TRELEGY ELLIPTA, a triple-combination inhaler for asthma and COPD, stands as a flagship product for GSK. Since its U.S. launch in 2017, the drug has experienced rapid growth driven by increasing prevalence of respiratory diseases and shifting treatment paradigms favoring combination therapies. This report analyzes its current market landscape, competitive positioning, growth forecasts, and the financial trajectory, incorporating current policies, patent considerations, and market trends influencing its future.

---

What Is TRELEGY ELLIPTA and How Does It Fit in the Market?

Component	Active Ingredients	Indication	Formulation	Approval Date
Fluticasone furoate	Glucocorticoid receptor agonist	Asthma, COPD	Once-daily inhaler	U.S. (2017), EU (2018)
Umeclidinium	Long-acting muscarinic antagonist	COPD
Vilanterol	Long-acting beta-agonist	Both conditions

Market positioning:
TRELEGY ELLIPTA combines three agents, offering a simplified regimen which improves patient adherence—a key factor in respiratory therapies. It addresses moderate-to-severe asthma and COPD, competing mainly with inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combinations like Symbicort and Advair, and LAMA/LABA combos such as Spiolto.

---

Market Size and Growth Trajectory

Global and U.S. Market Estimates

Market Segment	2019 (USD Billion)	2023 (Projected, USD Billion)	CAGR (2019-2023)	Key Drivers
COPD Therapeutics	15.2	19.3	8.0%	Aging population, rising smoking rates in developing nations.
Asthma Therapeutics	17.8	22.5	8.9%	Better diagnosis, inhaler device innovation.
Inhaler Market (Combined)	33.0	41.8	7.7%	Increased approvals of combination inhalers.

Sources: Grand View Research (2021), IQVIA (2022)

Market Share and Sales Trends

Year	Sales (USD Billion)	YoY Growth	Market Share of TRELEGY	Notes
2017	0.7	-	Minor share	Launch year, slow adoption
2019	1.6	128.6%	~12%	Rapid uptake in COPD, increased prescription
2021	2.8	75%	~15%	Steady growth, expanding indication use
2023 (est.)	4.2	50%	~20%	Market leader among triple combos

Note: Data from GSK Annual Reports, IQVIA

---

Drivers Influencing Market Dynamics

1. Epidemiological Trends

• Increasing COPD and asthma prevalence:
  The WHO reports >300 million asthma sufferers globally; COPD prevalence is projected to surpass 200 million by 2030. An aging population accelerates these trends.

• Urbanization and pollution:
  Exacerbate respiratory conditions, elevating demand for effective inhalers.

2. Treatment Paradigm Shifts

• Preference for triple therapy:
  Clinical guidelines now favor early initiation of triple inhalers for moderate-to-severe cases to reduce exacerbations, supporting TRELEGY’s market position.

• Adherence and convenience:
  Single-inhaler combination treatments improve compliance, critical for disease control.

3. Competitive Landscape

Key Competitors	Products	Market Share (2023)	Strengths	Weaknesses
GSK	TRELEGY ELLIPTA	20%	Strong efficacy, adherence	Patent protections, high price
AstraZeneca	Symbicort (ICS/LABA)	25%	Established brand	Less focus on triple combo
Novartis	Ultibro Breezhaler (LAMA/LABA)	10%	Low-cost alternative	Less effective in some subgroups
Boehringer Ingelheim	Spiolto (LAMA/LABA)	8%	Niche targeting	Limited indication scope

Regulatory and Patent Considerations

• Patent expiry:
  Original patents expire around 2028, opening market for generics and biosimilars, which could impact sales.

• Regulatory approvals:
  GSK’s further approvals for pediatric use and new indications could sustain growth.

Pricing and Reimbursement Policies

• Reimbursement landscape:
  In the U.S., CARES Act and CMS policies influence pricing; in Europe, national reimbursement schemes impact accessibility.

• Pricing strategies:
  GSK's premium pricing reflects clinical benefits, but price erosion due to biosimilar entry poses long-term risks.

---

Financial Forecasts and Revenue Projections

Year	Projected Sales (USD Billion)	Assumptions	Risks
2023	4.2	Continued growth, market penetration, favorable reimbursement	Patent expiry, increased competition
2024	4.8	Expanded indications, increased adherence programs	Patent challenges, cheaper alternatives entering the market
2025	5.5	Broader global adoption, new markets	Healthcare policy changes, biosimilar emergence
2026	6.3	Growth in emerging markets	Patent expiration, pricing pressures

Source: GSK Annual Reports, analyst estimates

Key Financial Drivers

• Market penetration rate:
  Increasing from ~20% in 2023 to over 35% in 2026 across COPD and asthma populations.

• Average Selling Price (ASP):
  Estimated at $250–$300 per inhaler in the U.S., with potential declines driven by biosimilar entry.

• Regulatory and policy impact:
  Cost containment policies favor generics, which may erode premium pricing.

---

Comparison with Competitors and Market Outlook

Parameter	TRELEGY ELLIPTA	Symbicort	Spiriva	Uptake and Adoption
Formulation	Triple inhaler (ICS/LAMA/LABA)	ICS/LABA	LAMA	Rapid growth in TRELEGY due to convenience
Indication	COPD, Asthma	COPD, Asthma	COPD, Asthma	Growing preference for triple therapy
Patent Status	Active until 2028; potential patents on device	Expired (patent cliff)	Patent expiration in 2024	Patent expirations open opportunities
Market Share (global)	~20% (2023)	~25%	~10%	Competitive, with TRELEGY increasing
Pricing	Premium	Moderate	Budget option	Pressure from biosimilars

Forecasts indicate TRELEGY’s dominance could stabilize within a niche or diminish if biosimilars reduce price premiums.

---

Regulatory Landscape and Policy Environment

Key Policies Affecting Market Trajectory

• FDA and EMA regulations (2022–2023):
  Accelerated approvals for combination inhalers, support for early multi-drug therapy.

• U.S. CMS Reimbursement Policies:
  Focus on value-based care incentivizes adherence, favoring products like TRELEGY.

• EU Pricing & Reimbursement Directive:
  Emphasizes cost-containment; risk of biosimilar competition.

Impact of Patent Expiry and Biosimilars

Year	Patent Expiry	Implications	Strategic Responses
2028	Patent expiration	Entry of biosimilars/genérics; potential revenue decline	Diversification, pipeline expansion, indications

---

Deep Dive: Economic Drivers and Challenges

1. Manufacturing and Supply Chain

• Complex inhaler device manufacturing:
  GSK’s investment in device innovation influences market exclusivity.

• Supply chain disruptions:
  COVID-19 highlighted vulnerabilities, impacting sales and inventory management.

2. Pricing Strategies and Market Access

• Premium pricing models have historically driven revenue but may face pressure ahead of patent expiry.

• Global access initiatives:
  GSK’s partnerships with governments in emerging markets aim to expand access, counteracting erosion of premium pricing.

3. Innovation and Pipeline Development

• Next-generation inhalers:
  GSK and competitors invest in inhalers offering improved delivery, reducing device errors.

• New indications:
  FDA approval for pediatric asthma in 2022 broadens potential market.

---

Future Outlook and Strategic Considerations

• Market growth driven by unmet needs in severe asthma and COPD management.

• Competitive threats from biosimilars and emerging therapies like biologics.

• Regulatory innovations, such as digital inhalers, could redefine adherence metrics.

• Partnerships and collaborations are critical for expanding indications and penetrating emerging markets.

---

Key Takeaways

• TRELEGY ELLIPTA’s success hinges on its efficacy, adherence benefits, and clinical guideline endorsements.

• The global COPD and asthma markets are sizable, with CAGR of approximately 8%, offering significant growth opportunities.

• Patent expiries starting in 2028 pose risks but also open avenues for biosimilar entry, potentially cutting into revenue.

• The landscape is highly competitive, with established products like Symbicort and Spiriva; continuous innovation is vital.

• Regulatory policies favor combination inhalers but are increasingly cost-conscious, emphasizing affordable access.

• GSK's strategy must balance innovation, pricing, pipeline expansion, and global access to sustain growth.

---

FAQs

1. When will TRELEGY ELLIPTA face patent expiry, and what are the implications?

Patent protection is active until approximately 2028. Post-expiry, biosimilar and generic competitors could erode market share, prompting GSK to innovate further, expand indications, or diversify its portfolio to sustain revenues.

2. How does TRELEGY compare to other inhalers in terms of efficacy and adherence?

Clinical trials demonstrate comparable or superior efficacy to dual therapies, with improved adherence rates due to once-daily, single-inhaler formulation, which reduces regimen complexity in chronic disease management.

3. What are the primary drivers of growth for TRELEGY's sales?

Key drivers include increasing prevalence of COPD and asthma, guideline recommendations favoring triple therapy, adherence improvements, and expanding global markets, especially in emerging economies.

4. How might regulatory changes affect TRELEGY's future sales?

Policies emphasizing cost-effective care and approval pathways for biosimilars may pressure pricing and market share. Conversely, expanded indications and digital health integrations could bolster growth.

5. What strategies is GSK employing to maintain TRELEGY’s market position?

GSK invests in pipeline expansion, develops next-generation inhalers, seeks new indications, enhances patient access programs, and collaborates globally to strengthen market presence.

---

Citations

1. Grand View Research. "Respiratory Drugs Market Size & Trends," 2021.
2. IQVIA. "The Impact of COVID-19 on Respiratory Disease Therapy," 2022.
3. GSK Annual Reports, 2017–2022.
4. World Health Organization. "Global Asthma Report," 2022.
5. FDA and EMA regulatory updates, 2022–2023.

---

In summary, TRELEGY ELLIPTA is positioned as a key growth driver in the respiratory therapeutics landscape, with a promising but evolving future shaped by demographic trends, regulatory environments, and competitive forces. Strategic agility and continuous innovation are essential for maximizing its financial trajectory.